Key result
The combination of ACE inhibitors, angiotensin-II receptor antagonists, and beta-blockers may produce adverse effects in heart failure, suggesting a need for caution with triple RAS inhibition.
Why the study?
Does the combination of ACE inhibitors, AR antagonists, and beta-blockers cause adverse effects in patients with heart failure?
Does the combination of ACE inhibitors, AR antagonists, and beta-blockers cause adverse effects in patients with heart failure?
Caution is warranted when combining ACE inhibitors, ARBs, and beta-blockers in heart failure patients due to potential adverse effects from excessive renin-angiotensin system inhibition.
Answers are grounded in this paper and cite their sources.
Caution urged with triple RAS inhibition in HF; leaves open optimal regimens for prospective trials.
Inhibitors of the renin-angiotensin system (RAS) are valuable therapeutic agents for a wide range of clinical conditions. Increasingly, consideration is being given to the combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor (AR) antagonists to obtain more complete inhibition of the RAS than can be achieved by either agent alone. Beta-blockers also inhibit the RAS by inhibiting renin secretion. Whereas the combination of an ACE inhibitor and AR antagonist represents dual RAS inhibition, the combination of both of these agents with beta-blocker therapy represents triple RAS inhibition. Animal studies indicate that complete blockade of the RAS produces adverse effects. Moreover, post-hoc analysis of the recent Valsartan Heart Failure Trial study suggests that the combination of ACE inhibitor and AR antagonist therapies may have an adverse effect in heart failure when combined with beta-blocker therapy. There is therefore a need for caution in the combination of ACE inhibition and AR antagonism, particularly in patients receiving beta-blockers, until the impact of this strategy is evaluated.
No takes yet. Share an insight, caveat, or question.
Duncan J. Campbell (2002) conducted a review in Heart failure. Triple renin-angiotensin system inhibition (ACE inhibitor, AR antagonist, and beta-blocker) was evaluated. The combination of ACE inhibitors, angiotensin-II receptor antagonists, and beta-blockers may produce adverse effects in heart failure, suggesting a need for caution with triple RAS inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: